Genuit Share Discussion Threads

[elgordo] 17/4/2005 21:28

I see that CMR Fuel Cells are shortlisted for the Carbon Trust Awards being announced this week, although you wouldn't know it from their or Generics' websites yet.

See tomorrow's (!) Carbon Trust press release at:

[t2_pgs] 11/4/2005 09:09

I'm sure I'm not the only person to notice that over the last few weeks all we have had is constant buying....all be it in fairly small volumes ...yet all thats happened is the price has dropped nearly 18% .......not very impressed I'm afraid!!!!!

[rambutan2] 16/3/2005 13:37

and up on some good volume this morning.

[rambutan2] 15/3/2005 14:15

so, they finally made it to profit on the consulting business...

In line with management expectations the consulting and
IP activities were profitable in Q4 2004 and break-even for the year as a whole.

Top-line growth was driven by a robust sales performance in Germany and the US,
in spite of the weakness of the dollar. The offices in Frankfurt and Boston are
now being grown in response to market demand...

well worth trudging through the whole statement. but my take is that they look set for a good 2005, with costs cut right down and profits in sight...
Outlook

The Group's activities have shown substantial performance improvement in 2004
over the previous three years. Following on from a strong fourth quarter, the
improvement in the trading performance of our technology consulting business is
continuing into 2005 with further top-line growth and a strong order book
carried forward.

The investment and asset management businesses are already benefiting from
improved conditions in the venture capital and AIM markets and we expect several
of our portfolio businesses to benefit from this improvement.

The Directors believe that careful investment in selected portfolio companies
and intellectual property, in an increasingly favourable market for early stage
technology and in conjunction with the improvement in the Group's consulting
activities, will enable the Group to increase value for shareholders in 2005.

[waldron] 15/3/2005 09:19

LONDON (AFX) - Generics Group AG said its full-year losses have narrowed
sharply on the back of a 17 pct rise in sales.
The company's pretax loss before minority interests was 2.9 mln stg, down
from an 11.1 mln loss a year earlier.
Sales from continuing operations increased by 17 pct to 15.7 mln stg.
tc

[waldron] 15/3/2005 07:07

RNS Number:7324J
Generics Group AG
15 March 2005


15 March 2005


THE GENERICS GROUP AG ('GENERICS')


PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2004


Generics, a leading integrated technology consulting, development and investment
organisation, today announces its preliminary results for the year ended 31
December 2004.


Highlights:


* Turnover from continuing operations increased by 17 % to #15.7m
(2003: #13.4m)

* Operating expenses reduced by 15 % to #19.3m (2003: #22.7m)

* Scientific Generics returned to profitability and growth during the
course of 2004 with strong sales performance in USA and Germany

* Total recognised losses relating to the year of #1.8m (2003: #10.2m)
with adjusted loss per share of 1.0 pence (2003: loss of 9.2 pence), including
expensed costs in spin-out and associated companies of #3.5m (2003: #6.4m).
Loss before tax and minority interests of #2.9m (2003: #11.1m)

* Successful refinancing of Atraverda Ltd during Q4 2004, raising #4.4m
over three tranches, including a grant of #0.9m. A gain of #0.5m has been
accounted for in the statement of total recognised gains and losses

* Multi-year licence deal signed in respect of AutosheathTM needle-stick
prevention technology

* Sale of Generics' investment in the automotive activities within
Sensopad Technologies Ltd for consideration of #1.2m during Q1 2004, and
downstream royalty agreement

* Year-end portfolio BVCA valuation of #11.6m (2003: #11.1m)

* Net assets per share of 9.3 pence at year end (2003: 10.2* pence)
before taking into account the BVCA portfolio valuation uplift equivalent to
2.9 pence per share (2003: 3.6* pence)
* Assumes Rights Issue occurred at 31 December 2003

* #7.3m raised via a fully underwritten Rights Issue following the EGM
in May 2004

* Creation of Hong Kong subsidiary - SGAI Ltd completed in Q1 2005 - to
extend the design and development capability of our consulting operation into
manufacturing



Gordon Edge, Generics' Chairman, commented:


"I am pleased to announce that at the end of 2004 our technology consulting and
development activities have returned to profitability and a number of our
investments including Sphere, CMR and Atraverda are making good commercial
progress.


During the year we sold the automotive interests of Sensopad Technologies to TT
electronics plc and successfully refinanced the battery activities in Atraverda.
This enabled the Group to reduce the total recognised losses for the year
substantially from #10.2m in 2003 to #1.8m. The Group successfully completed a
Rights Issue in June 2004 raising #7.3m. The additional cash resources together
with the recovery in our technology consulting and development activities now
places the Group in a robust position to build on the progress achieved in 2004.


Scientific Generics ended the year with a profitable fourth quarter and a strong
order book carried forward into 2005, having made excellent progress in Germany
and the USA during the year. Our German office was opened 2 years ago to provide
a focus for sales and operating in the German marketplace which accounts for
approximately one-third of our sales. During the year we also concluded a
substantial development contract and licence of our AutosheathTM needle stick
prevention technology.


High-quality technology innovation and design remains a hallmark of our
business. We were therefore delighted at the end of the year when Scientific
Generics was highly commended for its design collaborations on two world firsts
at the recent US 2005 International CES Innovations Design and Engineering
Awards. Working with St Jude Medical we helped to develop Housecall PlusTM, the
world's first monitoring system to transmit complex implantable defibrillator
data. We were also commissioned by Boardbug to design and develop a
multi-functional mobile monitor, the Boardbug Baby and Child MonitorTM. This
innovative form of child safety uses unique digital technology and won the 'Best
of Innovation' Award in the Personal Electronics category.


After the year-end we announced the launch of SGAI, our Hong Kong joint venture
with Automatic International Ltd ('AIL'), established to provide an integrated
end-to-end research, development and manufacturing capability. Through SGAI,
together with AIL and its parent company Automatic Manufacturing Ltd, we will
leverage the combined benefits and Hong Kong's strong intellectual property laws
and its proximity to mainland China for the provision of a range of flexible,
efficient and secure product development and manufacturing services to both new
and existing clients.


Within our investment portfolio, the recent commercial progress of Sphere
Medical Holding, CMR Fuel Cells and Atraverda has been encouraging. Each of
these portfolio companies is addressing very large market opportunities.
Atraverda has developed an innovative lead acid battery design using EbonexTM
bipolar membranes. The size of the global lead acid battery market is estimated
at $16.2 billion per year, growing steadily each year and the smaller and more
efficient Atraverda batteries are expected to be in high demand. CMR Fuel Cells,
created to exploit a revolutionary flow-through fuel cell using mixed reactants,
was spun out in Q1 2004 with The Carbon Trust and Conduit Ventures as Generics'
partners. CMR's patented technology involves electrochemical devices, which
convert fuel directly into electricity at high efficiency rates and have the
potential for higher power storage capacity. Sphere Medical Ltd was established
in a venture with Siemens to develop and market a new generation of monitoring
and diagnostic products for patients.


Our investment and technology consulting activities are on a firmer footing than
at any time in the last 3 years."


Enquiries:

The Generics Group AG (44) 1223 875200

Martin Frost Managing Director www.genericsgroup.com

Simon Davey CEO, Scientific Generics


Hansard Communications (44) 207 2451100

Adam Reynolds

Andy Tan

[rambutan2] 11/3/2005 15:42

and a quick visit to their website turns up this...

Upturn in UK innovation confirmed as Scientific Generics reach £1m UK sales YTD
08 March 2005
Scientific Generics has reached UK sales of more than £1m during the first two months of 2005 - a figure that took six months to reach the previous year. This upsurge in UK activity is symptomatic of a welcome rise in the level of innovative development work being undertaken by UK companies.

Following on from record sales for Scientific Generics at the end of 2004, revitalised UK sales has seen the organisation growing from strength to strength, creating the need for a recruitment drive to build on their world-class expertise and business offering in the UK.

New recruits in 2005 include: Ian Anderson, Managing Consultant specialising in the consumer and industrial sectors, who joins from competitor TTP; Dan Edwards, Harvard Business School graduate and 200th Sainsbury Management Fellow, who joins the 'technology strategy smart guys' in the Business Consulting division, and Jim Schoenenberger, appointed to a Senior Business Development role in the Sales and Marketing division, and who has a background with Cambridge businesses PA Consulting and CCL.

Simon Davey, CEO Scientific Generics said: "I'm really pleased to see our work with UK companies growing in this way. Innovation and effective exploitation of technology are vital to the success of UK industry, and Cambridge has long been in the forefront of this capability in the UK".

"We have also played a part in delivering the Government's commitment to technology development in the UK with some great successes in recent months;

such as our work with the DTI on the digital TV switchover, and the Innovation project with Yorkshire and Humber Regional Development Agency which is a £3m project to stimulate innovation in Yorkshire specifically in the Advanced Engineering and Metals Sector (AEM) and already has generated more than £21m in sales and over 200 jobs. We aim to take this project into other regions throughout the UK and Ireland."

John Golby, Director of Sales and Marketing, Scientific Generics said: "It is notable that our UK successes have come about not just from a single large contract, but from an increased interest in clients engaging us across all the sectors in which work. As a result Scientific Generics is attracting experienced senior consultants from other Cambridge-based consultancies."

[rambutan2] 11/3/2005 15:41

on a nice tight spread today of 11.25-11.5p. and someone picked up 200k on the button. finals are due soon (last year 2 april) so if optimistic then today might offer a good chance to top up/buy in?

[rambutan2] 28/2/2005 11:14

not a bad return so far but could be much more to come. interesting to see herald and artemis amongst the investors. and in full...

Sphere Medical Holding Limited secures £4,000,000 in next round financing

The Generics Group AG, a leading integrated technology consulting, development
and investment organisation, is pleased to announce that one of its portfolio
companies, a joint venture with Siemens Technology Accelerator GmbH, has
successfully raised a further £4,000,000 with a first closing of £3,196,250
(before expenses) from a series of institutional investors for further
development.

Sphere Medical Holding Limited ('Sphere') was incorporated to develop a series
of unique chip-based microsensors for use in intensive care medicine.

The funding was organised by Oakes, Lyman & Co Ltd with additional participation
by Springhill Bioventures, Herald Ventures, Artemis and Hotbed.

The size of the global in vitro diagnostic market is estimated at $23 billion
per annum, growing steadily each year particularly in the point-of-care sector
in which Sphere will operate. Sphere will be targeting the on-line measurement
of physiological parameters and anaesthetics segments of the market, which are
growing strongly.

The financing round capitalises the company at £7m. Generics has invested
£155,000 as part of the financing. Post the completion of the financing and
conversion of existing loans, Generics holds a 10.56 % fully diluted interest in
Sphere Medical.

Martin Frost, Managing Director of Generics, commented:

'We are very proud to see Sphere receive such wide spread support for the
development of its technology. In many ways we feel that this is a great
demonstration of our consultancy divisions' proficiency in identifing potential
commercial opportunities in under utilised intellectual property. Moreover,
taking Sphere to this point of its development demonstrates the way in which our
consultancy, development and investment divisions cooperate to fully capture the
commercial potential of new technologies.

We are delighted for the Sphere team and look forward to reporting on their
future progress.'

[maywillow] 28/2/2005 10:14

LONDON (AFX) - Generics Group AG said it holds 10.56 pct of Sphere Medical
Holding following a 4 mln stg financing round that values the developer of
chip-based microsensors for use in intensive care medicine at 7 mln stg.
Generics invested 155,000 stg as part of the financing.
Sphere is part of a joint venture with Siemens Technology Accelerator.
[e-mail]
ak/

[rambutan2] 21/1/2005 11:49

spose this was reason for rise over last week...

Cambridge & Hong Kong Joint Venture

The Generics Group AG ('Generics'), a leading integrated technology consulting,
development and investment organisation, is pleased to announce that its
wholly-owned subsidiary, Scientific Generics Limited ('Scientific Generics') has
entered into a Joint Venture ('JV') agreement with Automatic International
Limited ('AIL'), an associate of Automatic Manufacturing Limited ('AML'), to
provide an integrated end-to-end research, development and manufacturing
capability.

Together with its established Hong Kong manufacturing partner, AML, winner of
the 2004 Hong Kong Grand Award for Industry and founding chairman of the Hong
Kong Medical and Healthcare Device Manufacturers Association, Scientific
Generics has launched SGAI Tech Limited (SGAI) which will be based in Hong Kong.
Through SGAI, Scientific Generics and AML will leverage the combined benefits of
Hong Kong's intellectual property laws and its proximity to China for the
provision of a range of flexible, efficient and secure product development and
manufacturing services to both new and existing clients.

Scientific Generics is investing HK$1.323 million for 63% of the equity of the
JV and is providing a loan facility of up to HK$1.323 million. AIL is investing
HK$0.777 million for 37% of the equity of the JV and is providing a loan
facility of up to HK$0.777 million. A major key client has already been secured.

With the continued increase in off-shore manufacturing and the subsequent trend
towards off-shoring of development, it is important that the ability to deliver
innovative products in a cost effective and low-risk manner is not lost.

Recently Hong Kong has started to position itself as a technology transfer
gateway to the South China manufacturing region. SGAI will utilise Hong Kong's
growing knowledge based economy and high-tech infrastructure to link innovations
from Cambridge through to production in China.

Combining the world-class innovation skills of Scientific Generics with the
proven track record of AML, SGAI will focus on end-to-end delivery and provide
clients with an integrated approach to innovative product development and
production, which will mitigate the inherent commercial and technical risks of
off-shoring.

Clients will benefit from increased flexibility and greater efficiency in the
product development process. SGAI aims to offer a flexible method of charging
for the cost of research and development - enabling companies with small R&D
budgets but large purchasing power to specify and create their own innovative
products. This will provide significant advantage to certain market sectors by
affording them the ability to move away from 'me-too' products.

All manufacturing work will utilise the ISO 9001, ISO 13485, cGMP, FDA and SFDA
compliant, QS 9000 approved manufacturing facilities of AML. These facilities,
based in Dongguan, China, with 330,000 square feet of production facilities and
a 4,000 strong work force, will enhance SGAI's range of capabilities from
assembly design and proof-of-principle prototyping to testing, approval and full
manufacture.

Dr Tim Moore, Managing Consultant at Scientific Generics, has been appointed
Chief Executive Officer of SGAI.

Simon Davey, CEO, Scientific Generics, commented:

'The creation of SGAI represents a turning-point for hi-tech design
consultancies in the UK. Linking Cambridge directly with Hong Kong and China
enables us to translate clients needs into product realisation. Through an
integrated innovative process SGAI will deliver outstanding quality in a low
risk, efficient and rapid manner. Hong Kong is key to protecting intellectual
property when developing products in China and its new research facilities,
including the Hong Kong Science and Technology Park, make it an ideal place for
mid-cap and start-up companies to leverage the value of China.'

John Mok, Chairman, AML, commented:

'SGAI will enable AML to build on its reputation for high quality and controlled
manufacturing through access to new markets with innovative products. Based in
Hong Kong and southern China, AML is ideally placed to take full advantage of
the new Hong Kong economy through SGAI.'


AUTOMATIC MANUFACTURING LIMITED

AML was founded in 1976 as a Hong Kong based electronic products manufacturing
company. AML is an ISO 9001, ISO 13485, cGMP, FDA & SFDA compliant and QS 9000
approved manufacturer.

AML provides multi-technology design and manufacturing services for medical
devices, automotive electronics, telecoms products, office equipment, home
automation & industrial controls, etc. With recent expansion, AML owns around
330,000 square feet production facilities and has over 4,000 employees.

www.automatic.com.hk

[mbbx6rah] 21/1/2005 10:52

Is anyone looking at this stock today ?
Quite a positive announcement, but not alot of buying yet

[rambutan2] 18/1/2005 11:17

hasnt dropped back today. yet.

[maxwellsdemon] 17/1/2005 15:17

New patent application. Published 13 Jan 2005

12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(11) WO 2005/003687
(13) A2


(21) PCT/GB2004/002928

(22) 05 July 2004 (05.07.2004)

(25) English
(26) English

(30) 0315738.5 04 July 2003
(04.07.2003) GB
(43) 13 January 2005 (13.01.2005)
(51)7 G01D 5/20
(54) POSITION ENCODER
(71) SCIENTIFIC GENERICS LIMITED [GB/GB]; Harston Mill, Harston, Cambridge CB2 5GG (GB).
(72)
(75) KREIT, Darran [GB/GB]; Scientific Generics Limited, Harston Mill, Harston, Cambridge CB2 5GG (GB). SILLS, Colin [GB/GB]; Scientific Generics Limited, Harston Mill, Harston, Cambridge CB2 5GG (GB). HOWARD, Mark [GB/GB]; Scientific Generics Limited, Harston Mill, Harston, Cambridge CB2 5GG (GB).
(74) BERESFORD, Keith, Denis, Lewis et al.; Beresford & Co, 16 High Holborn, London WC1V 6BX (GB).
(81) AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
(84) ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

For information on time limits for entry into the national phase please click here
Published
-- without international search report and to be republished upon receipt of that report


(57) There is described a position sensor in which a first Aerial and a second aerial are provided on plural planar substrates which are arranged in parallel with each other. A sensor element is operable to move relative to the plurality of planar substrates along a measurement direction transverse to the planar substrates. By appropriately distributing conductive tracks on at least two planar surfaces of the Plurality of planar substrates, the orthogonal position of a sensor element relative to the planar substrates may be detected.

[rambutan2] 17/1/2005 14:01

has doubled since october.

[hvs] 17/1/2005 13:45

Its going to 20p very very quickly now.

[rambutan2] 17/1/2005 09:02

and again this morning, with a 150k buy at 13p.
somethings brewing but dont know what?

[tony14] 14/1/2005 11:51

Tasty move today, have they been tipped? ;-))

[hvs] 14/1/2005 11:50

Nice uptick today and plenty more to come.

[rambutan2] 30/12/2004 15:26

this got tipped as a best buy in the xmas ic.
thought it might have provoked a post or two?

[rambutan2] 21/12/2004 14:43

read somewhere that top property manager chris turner (amongst others) is now keen on commercial property and has recently bought into the cambridge science park. augers better for the big building?

[maxwellsdemon] 14/12/2004 12:55

Sphere Medical's web site: